• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Tempus AI Inc.

    8/8/24 4:38:12 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology
    Get the next $TEM alert in real time by email
    SC 13G 1 formsc13g.htm Proof -

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

     

    Tempus AI, Inc.

    (Name of Issuer)

     

    Class A Common Stock

    (Titles of Class of Securities)

     

    71535D106

    (CUSIP Number)

     

    June 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    1  

    Name of Reporting Person

     

    BK TL21 LLC

    2  

    Check the Appropriate Box if a Member of a Group

    (a) ☐ (b) ☐

     

    3  

    SEC Use Only

     

    4  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

      5  

    Sole Voting Power

     

    0

      6  

    Shared Voting Power

     

    16,560,249

      7  

    Sole Dispositive Power

     

    0

      8  

    Shared Dispositive Power

     

    16,560,249

    9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,560,249

    10  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11  

    Percent of Class Represented by Amount in Row 9

     

    11.1%1

    12  

    Type of Reporting Person

     

    CO

     

     

    1 Based on 149,274,923 shares outstanding as reported the issuer’s Form 10-Q for the quarterly period ended June 30, 2024 filed with the SEC on August 6, 2024.

     

     
     

     

    1  

    Name of Reporting Person

     

    Bradley Keywell

    2  

    Check the Appropriate Box if a Member of a Group

    (a) ☐ (b) ☐

     

    3  

    SEC Use Only

     

    4  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

      5  

    Sole Voting Power

     

    16,560,249

      6  

    Shared Voting Power

     

    0

      7  

    Sole Dispositive Power

     

    0

      8  

    Shared Dispositive Power

     

    16,560,249

    9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    16,560,249

    10  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    ☐

    11  

    Percent of Class Represented by Amount in Row 9

     

    11.1%2

    12  

    Type of Reporting Person

     

    IN

     

     

    2 Based on 149,274,923 shares outstanding as reported the issuer’s Form 10-Q for the quarterly period ended June 30, 2024 filed with the SEC on August 6, 2024.

     

     
     

     

    Item 1(a). Name of Issuer:

     

    Tempus AI, Inc.

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    600 West Chicago Avenue, Suite 510

     

    Chicago, Illinois 60654

     

    Item 2(a). Name of Person Filing:

     

    This Schedule 13G is being filed by the following persons (each, a “Reporting Person”):

     

    i. BK TL21 LLC (“BK”)

     

    ii. Bradley Keywell (“Keywell”)

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    The principal business address of each of the Reporting Persons is:

     

    4603 Franklin Pike

     

    Nashville, Tennessee 37220

     

    Item 2(c). Citizenship:

     

    BK is organized under the laws of the State of Delaware.

     

    Keywell is a citizen of the United States.

     

    Item 2(d). Titles of Classes of Securities:

     

    Class A Common Stock, par value $0.0001 per share (the “Shares”).

     

    Item 2(e). CUSIP Number:

     

    71535D106

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership

     

    (a) Amount beneficially owned:

     

    See response to Item 9 on each Reporting Person’s cover page.

     

    (b) Percent of class:

     

    See response to Item 11 on Reporting Person’s cover page.

     

    (c) Number of shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote:

     

    See response to Item 5 on each Reporting Person’s cover page.

     

     
     

     

    (ii) Shared power to vote or to direct the vote:

     

    See response to Item 6 on each Reporting Person’s cover page.

     

    (iii) Sole power to dispose or to direct the disposition of:

     

    See response to Item 7 on each Reporting Person’s cover page.

     

    (iv) Shared power to dispose or to direct the disposition of:

     

    See response to Item 8 on each Reporting Person’s cover page.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 8, 2024

     

      BK TL21 LLC.
         
      By: /s/ Bradley Keywell
      Name:  Bradley Keywell
      Title: Manager

     

      /s/ Bradley Keywell
      Bradley Keywell

     

     

     

    Get the next $TEM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TEM

    DatePrice TargetRatingAnalyst
    6/2/2026Peer Perform
    Wolfe Research
    4/13/2026$35.00Underperform
    Jefferies
    4/13/2026$65.00Hold → Buy
    TD Cowen
    2/19/2026$100.00Outperform
    Mizuho
    2/17/2026$59.00Outperform
    Robert W. Baird
    12/2/2025$85.00Overweight
    Morgan Stanley
    10/21/2025$88.00Buy → Hold
    TD Cowen
    10/20/2025$110.00Buy
    Canaccord Genuity
    More analyst ratings

    $TEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Epstein David R sold $12,350 worth of shares (250 units at $49.40) as part of a pre-agreed trading plan, decreasing direct ownership by 0.79% to 31,464 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    6/3/26 4:28:50 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    CEO and Chairman Lefkofsky Eric P sold $7,763,312 worth of shares (166,250 units at $46.70) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    5/29/26 4:15:14 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Director Belcher Eric D was granted 5,913 units of Class A Comnmon Stock, increasing direct ownership by 38% to 21,424 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    5/26/26 9:46:10 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of a digital pathology IMS Open-Source Consortium ("IMS Consortium"). Designed to accelerate the democratization and standardization of digital pathology, the consortium aims to bring together leading academic medical centers and industry partners to develop a best-in-class open-source digital pathology platform and viewer. YNHH and MSK are founding academic members of the consortium. As pioneering institutions, they will contribute to defining the vision, governance, and stra

    6/3/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH, a next-generation sequencing (NGS) test that uses a whole-genome sequencing (WGS) approach for the detection of actionable oncologic targets in peripheral blood and bone marrow samples from patients with hematologic malignancies. Tempus first announced the xH assay for research use only in January 2025. The test was developed for use in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and overlap syndromes (MDS/MPN). It is optimized for myeloid neoplasms and is designed to su

    6/1/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform designed to accelerate drug development and research. This evolution seamlessly connects Tempus' multimodal data, AI tooling and computational infrastructure to deliver actionable insights at the pace required for drug development. The next-generation of the Lens platform is built on over a decade of longitudinal real-world data and years of expertise translating that data into actionable evidence for biopharma. Lens combines one of the world's largest real-world multimodal datasets, high-

    5/31/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    SEC Filings

    View All

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    5/27/26 4:45:23 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 8-K filed by Tempus AI Inc.

    8-K - Tempus AI, Inc. (0001717115) (Filer)

    5/22/26 4:01:21 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    5/20/26 5:05:52 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tempus Ai, Inc. bought $2,739,181 worth of shares (320,267 units at $8.55), increasing direct ownership by 3% to 13,039,067 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    2/13/26 5:24:46 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    8/20/24 4:17:55 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on Tempus AI

    Wolfe Research resumed coverage of Tempus AI with a rating of Peer Perform

    6/2/26 8:38:27 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Jefferies initiated coverage on Tempus AI with a new price target

    Jefferies initiated coverage of Tempus AI with a rating of Underperform and set a new price target of $35.00

    4/13/26 9:01:23 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI upgraded by TD Cowen with a new price target

    TD Cowen upgraded Tempus AI from Hold to Buy and set a new price target of $65.00

    4/13/26 8:40:42 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Financials

    Live finance-specific insights

    View All

    Tempus Reports First Quarter 2026 Results

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. Revenue of $348.1 million, up 36.1% year-over-year Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% MRD volume was ~6,500 tests in Q1 2026, up ~500% year-over-year Data and Applications revenue of $87.0 million, representing 40.5% year-over-year growth, with Insights (data licensing and modeling) growing 44.1% $643.8 million in cash and marketable securities as of March 31, 2026 Increasing revenue guidan

    5/5/26 4:01:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report First Quarter 2026 Financial Results on May 5

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 5, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the "Events" section of the Tempus Investor Relations website. For those unable to listen to the live broadcast, a recording will be available on the website following the call. Alt

    4/21/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4652845 United States - New York: (646) 307-1963 USA & Canada - Toll-Free: (800) 715-9871 Live Webcast: https://edge.media-

    2/10/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Leadership Updates

    Live Leadership Updates

    View All

    Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of a digital pathology IMS Open-Source Consortium ("IMS Consortium"). Designed to accelerate the democratization and standardization of digital pathology, the consortium aims to bring together leading academic medical centers and industry partners to develop a best-in-class open-source digital pathology platform and viewer. YNHH and MSK are founding academic members of the consortium. As pioneering institutions, they will contribute to defining the vision, governance, and stra

    6/3/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.

    Oran Muduroglu, proven medical imaging entrepreneur, to lead U.S. launch of eyonis® LCS Established U.S. commercial and clinical infrastructure combined with Medicare reimbursement pathway already in place to support expansion Active discussions underway to establish key clinical partnerships to support broad access across U.S. lung cancer screening programs Webcasts will be held on February 26, 2026, to discuss the Company's recent achievements and upcoming milestones for eyonis® LCS deployment in the U.S. Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218440005/en/Oran Muduroglu Appointed Presi

    2/18/26 11:45:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland. "We're excited to join the oncology community at this year's meeting and highlight our latest research and progress in advancing the immuno-oncology field," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "Our latest findings demonstrate the potential of integrated, data-driven approaches to refine biomarkers, im

    11/5/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 5:00:02 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 4:30:28 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

    SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

    8/20/24 4:27:51 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology